California State Teachers Retirement System Decreases Position in Haemonetics Corporation (HAE)

California State Teachers Retirement System cut its stake in shares of Haemonetics Corporation (NYSE:HAE) by 7.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 92,891 shares of the medical instruments supplier’s stock after selling 7,921 shares during the quarter. California State Teachers Retirement System owned 0.18% of Haemonetics Corporation worth $3,668,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently made changes to their positions in the company. Shine Investment Advisory Services Inc. bought a new stake in shares of Haemonetics Corporation during the 2nd quarter valued at approximately $132,000. Riverhead Capital Management LLC grew its holdings in shares of Haemonetics Corporation by 79.3% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,407 shares of the medical instruments supplier’s stock valued at $135,000 after purchasing an additional 1,507 shares during the last quarter. Pacad Investment Ltd. bought a new stake in shares of Haemonetics Corporation during the 2nd quarter valued at approximately $174,000. Shelton Capital Management bought a new stake in shares of Haemonetics Corporation during the 2nd quarter valued at approximately $204,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Haemonetics Corporation during the 2nd quarter valued at approximately $260,000.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.com-unik.info/2017/11/06/california-state-teachers-retirement-system-decreases-position-in-haemonetics-corporation-hae.html.

Several brokerages recently issued reports on HAE. TheStreet raised shares of Haemonetics Corporation from a “c” rating to a “b-” rating in a report on Monday, August 7th. BidaskClub raised shares of Haemonetics Corporation from a “strong sell” rating to a “sell” rating in a report on Tuesday, August 8th. Zacks Investment Research raised shares of Haemonetics Corporation from a “hold” rating to a “buy” rating and set a $47.00 price target on the stock in a report on Wednesday, August 9th. Barrington Research raised shares of Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $48.00 price target on the stock in a report on Tuesday, August 8th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $43.00 price target (up from $38.00) on shares of Haemonetics Corporation in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $45.83.

Shares of Haemonetics Corporation (NYSE HAE) opened at $47.12 on Monday. Haemonetics Corporation has a 1-year low of $33.09 and a 1-year high of $47.98. The company has a current ratio of 2.57, a quick ratio of 1.72 and a debt-to-equity ratio of 0.31. The firm has a market cap of $2,478.81, a P/E ratio of 29.27, a price-to-earnings-growth ratio of 3.73 and a beta of 0.91.

Haemonetics Corporation (NYSE:HAE) last posted its earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.02. Haemonetics Corporation had a net margin of 0.48% and a return on equity of 11.07%. The firm had revenue of $211.00 million for the quarter, compared to analyst estimates of $211.29 million. During the same period in the previous year, the firm posted $0.25 EPS. The company’s revenue for the quarter was up .5% compared to the same quarter last year. equities analysts predict that Haemonetics Corporation will post 1.61 earnings per share for the current fiscal year.

Haemonetics Corporation Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics Corporation (NYSE:HAE)

What are top analysts saying about Haemonetics Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Haemonetics Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit